Ready to Use: Supplied as a liquid formulation, eliminating the need to reconstitute lyophilised peptide powder before research
Schwartz K, Chang HT, Nikolai M, Pernicone J, Rhee S, Olson K et al
This strategic acquisition will enhance Novo Holdings' portfolio by integrating Catalent's expertise in drug delivery technologies, biologics, and gene therapies, ultimately strengthening its position in the global healthcare market
In the STEP 1 trial of the FDA-approved branded product, adults lost about 15% of body weight on average over 68 weeks alongside lifestyle changes, and roughly one in three lost 20% or more
The efficacy of semaglutide in helping with weight loss medications is so well-documented that it has been FDA-approved for weight loss in individuals who are overweight or obese